ResearcherChugai Pharmaceutical Co., Ltd. (Japan)No recent work listed

Tadashi Ishii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1204-4716; OpenAlex author ID A5004465942. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2017: 1 paper

Papers 1

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Last author DOI 10.1093/jjco/hyx075 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wataru Ichikawa · 1 shared paper, 2017 · strength 0.08
- Paper Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. DOI 10.1093/jjco/hyx075 ↗
Junji Furuse · 1 shared paper, 2017 · strength 0.08
- Paper Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. DOI 10.1093/jjco/hyx075 ↗
Takuji Okusaka · 1 shared paper, 2017 · strength 0.08
- Paper Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. DOI 10.1093/jjco/hyx075 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.